Former Gilead Sciences R&D chief Norbert Bischofberger named CEO of Kronos Bio

Former Gilead Sciences R&D chief Norbert Bischofberger named CEO of Kronos Bio

Kronos Bio on Wednesday announced the appointment of former Gilead Sciences head of R&D Norbert Bischofberger as its CEO.

The news comes after Bischofberger disclosed in March his intention to leave the drugmaker at the end of last month, having joined the company in 1990.

Bischofberger remarked “the science behind Kronos is compelling,” with the company currently advancing two preclinical programmes targeting MYC and the androgen receptor for the treatment of cancer.

May 23rd, 2018

https://www.firstwordpharma.com/

May 23, 2018 / Pharma News